The abstract is read at the publisher; the summary is JClub's.
Geographic availability of the minimum health care infrastructure needed for subcutaneous anti-amyloid Alzheimer disease therapy varies by age and location across the US.
- Why it matters: Access to the required infrastructure may differ across communities and patient age groups, creating potential barriers to receiving subcutaneous Alzheimer disease treatment.
- What they did: In a cross-sectional analysis, the study mapped nationwide geographic availability of the minimum infrastructure for subcutaneous anti-amyloid therapy and examined variation by age and location.
- The result: The findings identify where infrastructure is more or less available, informing planning for equitable access to subcutaneous Alzheimer disease therapy across the US.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.